## CITATION REPORT List of articles citing

Weight reduction and ursodeoxycholic acid in subjects with nonalcoholic fatty liver disease. A double-blind, placebo-controlled trial

DOI: PM/15505596 Annals of Hepatology, 2004, 3, 108-12.

Source: https://exaly.com/paper-pdf/132634130/citation-report.pdf

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
18	Nonalcoholic Fatty Liver Disease (NAFLD): Approach in the Adolescent Patient. <i>Current Treatment Options in Gastroenterology</i> , <b>2006</b> , 9, 423-31	2.5	17
17	Neue Therapiem glichkeiten bei nichtalkoholischer Fettleber. <i>Diabetologe</i> , <b>2007</b> , 3, 202-210	0.2	1
16	Current status of therapy in nonalcoholic Fatty liver disease. <i>Therapeutic Advances in Gastroenterology</i> , <b>2009</b> , 2, 29-43	4.7	9
15	Identification and treatment of metabolic complications in pediatric obesity. <i>Reviews in Endocrine and Metabolic Disorders</i> , <b>2009</b> , 10, 167-88	10.5	44
14	Effects of metformin and weight loss on serum alanine aminotransferase activity in the diabetes prevention program. <i>Obesity</i> , <b>2010</b> , 18, 1762-7	8	42
13	Treatment options for nonalcoholic fatty liver disease. <i>Therapeutic Advances in Gastroenterology</i> , <b>2010</b> , 3, 121-37	4.7	103
12	Endoplasmic reticulum stress and the unfolded protein response in nonalcoholic fatty liver disease. <i>Antioxidants and Redox Signaling</i> , <b>2011</b> , 15, 505-21	8.4	75
11	Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. <i>Diabetologia</i> , <b>2012</b> , 55, 885-904	10.3	444
10	Lifestyle interventions for the treatment of non-alcoholic fatty liver disease. <i>Hepatic Medicine:</i> Evidence and Research, <b>2014</b> , 6, 1-10	3.4	5
9	A Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLD. <i>Gastroenterology Research and Practice</i> , <b>2016</b> , 2016, 7109270	2	42
8	Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD): an attempted network meta-analysis. <i>The Cochrane Library</i> , <b>2017</b> , 3, CD011640	5.2	28
7	Impact of ursodeoxycholic acid on circulating lipid concentrations: a systematic review and meta-analysis of randomized placebo-controlled trials. <i>Lipids in Health and Disease</i> , <b>2019</b> , 18, 88	4.4	14
6	Effect of ursodeoxycholic acid on liver markers: A systematic review and meta-analysis of randomized placebo-controlled clinical trials. <i>British Journal of Clinical Pharmacology</i> , <b>2020</b> , 86, 1476-14	183 <sup>8</sup>	8
5	Defective Cytochrome P450-Catalysed Drug Metabolism in Niemann-Pick Type C Disease. <i>PLoS ONE</i> , <b>2016</b> , 11, e0152007	3.7	17
4	The Evaluation of Effective Drugs for the Treatment of Non-Alcoholic Fatty Liver Disease: A Systematic Review and Network Meta-Analysis. <i>Advanced Pharmaceutical Bulletin</i> , <b>2020</b> , 10, 542-555	4.5	3
3	Nonalcoholic fatty liver disease: an overview of current insights in pathogenesis, diagnosis and treatment. <i>World Journal of Gastroenterology</i> , <b>2008</b> , 14, 2474-86	5.6	135
2	Pediatric nonalcoholic fatty liver disease: overview with emphasis on histology. <i>World Journal of Gastroenterology</i> , <b>2010</b> , 16, 5280-5	5.6	34

The endoplasmic reticulum as a potential therapeutic target in nonalcoholic fatty liver disease. Current Opinion in Investigational Drugs, 2008, 9, 1084-8

15